PubMed for id: 9133

Year	Number of Results
1991	1
1994	3
1995	5
1997	1
1998	3
1999	1
2000	3
2001	2
2002	4
2003	3
2004	5
2006	1
2007	5
2008	2
2009	5
2010	4
2011	2
2012	2
2013	6
2014	3
2015	8
2016	3
2017	2
2018	1
2019	8
2020	6
2021	7
2022	5
2023	2
2024	4

1

Upregulation of CCNB2 and a novel lncRNAs-related risk model predict prognosis in clear cell renal cell carcinoma.

Ren C, Wang Q, Xu Z, Pan Y, Wang S, Liu X. Ren C, et al. J Cancer Res Clin Oncol. 2024 Feb 1;150(2):64. doi: 10.1007/s00432-024-05611-x. J Cancer Res Clin Oncol. 2024. PMID: 38300330 Free PMC article.

2

CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex.

Wang Z, Li M, Liu Y, Qiao Z, Yang L, Liu B, Bai T. Wang Z, et al. Cancer Gene Ther. 2022 Aug;29(8-9):1217-1227. doi: 10.1038/s41417-021-00423-4. Epub 2022 Jan 27. Cancer Gene Ther. 2022. PMID: 35082401

3

CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.

Wang D, Sun H, Li X, Wang G, Yan G, Ren H, Hou B. Wang D, et al. Biosci Rep. 2022 Jan 28;42(1):BSR20211939. doi: 10.1042/BSR20211939. Biosci Rep. 2022. PMID: 34908101 Free PMC article.

4

Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo.

Wu S, Su R, Jia H. Wu S, et al. Dis Markers. 2021 Jul 26;2021:5511041. doi: 10.1155/2021/5511041. eCollection 2021. Dis Markers. 2021. PMID: 34354775 Free PMC article.

5

Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis.

Li R, Jiang X, Zhang Y, Wang S, Chen X, Yu X, Ma J, Huang X. Li R, et al. Arch Med Res. 2019 Jan;50(1):10-17. doi: 10.1016/j.arcmed.2019.03.003. Epub 2019 Apr 4. Arch Med Res. 2019. PMID: 31101236

6

The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder cancer.

Lei CY, Wang W, Zhu YT, Fang WY, Tan WL. Lei CY, et al. Urol Oncol. 2016 May;34(5):237.e1-10. doi: 10.1016/j.urolonc.2015.11.011. Epub 2015 Dec 17. Urol Oncol. 2016. PMID: 26706119

7

CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients.

Qian X, Song X, He Y, Yang Z, Sun T, Wang J, Zhu G, Xing W, You C. Qian X, et al. Biomed Pharmacother. 2015 Aug;74:222-7. doi: 10.1016/j.biopha.2015.08.004. Epub 2015 Aug 28. Biomed Pharmacother. 2015. PMID: 26349989

8

Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer.

Takashima S, Saito H, Takahashi N, Imai K, Kudo S, Atari M, Saito Y, Motoyama S, Minamiya Y. Takashima S, et al. Tumour Biol. 2014 May;35(5):4257-65. doi: 10.1007/s13277-013-1556-7. Epub 2013 Dec 28. Tumour Biol. 2014. PMID: 24375198

9

Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome.

Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P, Helou K. Shubbar E, et al. BMC Cancer. 2013 Jan 2;13:1. doi: 10.1186/1471-2407-13-1. BMC Cancer. 2013. PMID: 23282137 Free PMC article.

10

Use of serum circulating CCNB2 in cancer surveillance.

Mo ML, Chen Z, Li J, Li HL, Sheng Q, Ma HY, Zhang FX, Hua YW, Zhang X, Sun DQ, Xu ML, Niu RG, Xu JP, Zuo HJ, Liu M, Zhou HM. Mo ML, et al. Int J Biol Markers. 2010 Oct-Dec;25(4):236-42. Int J Biol Markers. 2010. PMID: 21161946

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year